Michael Matson
Stock Analyst at Needham
(4.05)
# 1,630
Out of 4,456 analysts
1559
Total ratings
48.5%
Success rate
5.1%
Average return
Main Sectors:
Stocks Rated by Michael Matson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AORT Artivion | Reiterated: Buy | $44 | $22.92 | +92.01% | 59 | Jun 29, 2026 | |
| INMD InMode | Maintained: Hold | n/a | $14.57 | - | 40 | Jun 24, 2026 | |
| MDT Medtronic | Reiterated: Buy | $101 | $81.52 | +23.90% | 97 | Jun 17, 2026 | |
| TMDX TransMedics Group | Maintained: Buy | $142 | $67.10 | +111.62% | 28 | Jun 9, 2026 | |
| VCYT Veracyte | Reiterated: Buy | $48 → $57 | $59.53 | -4.25% | 35 | Jun 1, 2026 | |
| ICUI ICU Medical | Upgraded: Buy | $165 | $147.08 | +12.18% | 13 | May 27, 2026 | |
| BSX Boston Scientific | Reiterated: Buy | $77 | $44.05 | +74.80% | 126 | May 18, 2026 | |
| ENOV Enovis | Maintained: Buy | $52 | $22.17 | +134.60% | 17 | May 18, 2026 | |
| RMD ResMed | Maintained: Hold | n/a | $201.10 | - | 94 | May 15, 2026 | |
| IMDX Insight Molecular Diagnostics | Maintained: Buy | $9 | $5.35 | +68.38% | 35 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $1.04 | +189.86% | 32 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $215.58 | - | 33 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $6.99 | +71.80% | 86 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $13.39 | -10.38% | 37 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $77.01 | - | 46 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $147 | $127.75 | +15.07% | 69 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $28.16 | +59.83% | 101 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $81 | $82.63 | -1.97% | 86 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $86 | $88.13 | -2.42% | 10 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $101 → $90 | $71.00 | +26.76% | 68 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $454 → $418 | $333.66 | +25.28% | 73 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $20.38 | +47.20% | 51 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $36 | $34.30 | +4.84% | 81 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $14.14 | +6.08% | 38 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $92.28 | - | 88 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $316.25 | - | 24 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.04 | n/a | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $65 → $82 | $84.91 | n/a | 22 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 | $17.20 | n/a | 1 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.92 | n/a | 50 | Dec 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $1.86 | n/a | 10 | Nov 11, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1 | $8.47 | n/a | 1 | Nov 6, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $636 | $407.21 | n/a | 1 | Apr 19, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $15 → $14 | $7.11 | n/a | 4 | Apr 9, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $9.62 | n/a | 1 | Apr 17, 2009 |
Artivion
Jun 29, 2026
Reiterated: Buy
Price Target: $44
Current: $22.92
Upside: +92.01%
InMode
Jun 24, 2026
Maintained: Hold
Price Target: n/a
Current: $14.57
Upside: -
Medtronic
Jun 17, 2026
Reiterated: Buy
Price Target: $101
Current: $81.52
Upside: +23.90%
TransMedics Group
Jun 9, 2026
Maintained: Buy
Price Target: $142
Current: $67.10
Upside: +111.62%
Veracyte
Jun 1, 2026
Reiterated: Buy
Price Target: $48 → $57
Current: $59.53
Upside: -4.25%
ICU Medical
May 27, 2026
Upgraded: Buy
Price Target: $165
Current: $147.08
Upside: +12.18%
Boston Scientific
May 18, 2026
Reiterated: Buy
Price Target: $77
Current: $44.05
Upside: +74.80%
Enovis
May 18, 2026
Maintained: Buy
Price Target: $52
Current: $22.17
Upside: +134.60%
ResMed
May 15, 2026
Maintained: Hold
Price Target: n/a
Current: $201.10
Upside: -
Insight Molecular Diagnostics
May 14, 2026
Maintained: Buy
Price Target: $9
Current: $5.35
Upside: +68.38%
May 14, 2026
Reiterated: Buy
Price Target: $3
Current: $1.04
Upside: +189.86%
May 12, 2026
Maintained: Hold
Price Target: n/a
Current: $215.58
Upside: -
May 8, 2026
Maintained: Buy
Price Target: $12
Current: $6.99
Upside: +71.80%
May 8, 2026
Reiterated: Buy
Price Target: $12
Current: $13.39
Upside: -10.38%
May 7, 2026
Maintained: Hold
Price Target: n/a
Current: $77.01
Upside: -
May 7, 2026
Maintained: Buy
Price Target: $147
Current: $127.75
Upside: +15.07%
May 6, 2026
Reiterated: Buy
Price Target: $45
Current: $28.16
Upside: +59.83%
May 6, 2026
Reiterated: Buy
Price Target: $81
Current: $82.63
Upside: -1.97%
May 6, 2026
Reiterated: Buy
Price Target: $86
Current: $88.13
Upside: -2.42%
May 1, 2026
Maintained: Buy
Price Target: $101 → $90
Current: $71.00
Upside: +26.76%
May 1, 2026
Reiterated: Buy
Price Target: $454 → $418
Current: $333.66
Upside: +25.28%
May 1, 2026
Reiterated: Buy
Price Target: $30
Current: $20.38
Upside: +47.20%
Apr 30, 2026
Maintained: Hold
Price Target: $36
Current: $34.30
Upside: +4.84%
Apr 29, 2026
Maintained: Buy
Price Target: $15
Current: $14.14
Upside: +6.08%
Apr 28, 2026
Maintained: Hold
Price Target: n/a
Current: $92.28
Upside: -
Feb 25, 2026
Maintained: Hold
Price Target: n/a
Current: $316.25
Upside: -
Apr 5, 2024
Downgraded: Hold
Price Target: n/a
Current: $0.04
Upside: n/a
May 5, 2021
Maintained: Buy
Price Target: $65 → $82
Current: $84.91
Upside: n/a
Mar 18, 2020
Maintained: Buy
Price Target: $27
Current: $17.20
Upside: n/a
Dec 6, 2018
Rated: Hold
Price Target: n/a
Current: $3.92
Upside: n/a
Nov 11, 2016
Maintained: Buy
Price Target: n/a
Current: $1.86
Upside: n/a
Nov 6, 2015
Reiterated: Buy
Price Target: $1
Current: $8.47
Upside: n/a
Apr 19, 2013
Maintained: Buy
Price Target: $636
Current: $407.21
Upside: n/a
Apr 9, 2013
Upgraded: Buy
Price Target: $15 → $14
Current: $7.11
Upside: n/a
Apr 17, 2009
Downgraded: Sell
Price Target: n/a
Current: $9.62
Upside: n/a